公开(公告)号：US5130449A

公开(公告)日：1992-07-14

申请号：US521311

申请日：1990-05-09

Applicant: Michel Lagarde ,  Helmut Traitler ,  Hans-Juergen Wille

Inventor： Michel Lagarde ,  Helmut Traitler ,  Hans-Juergen Wille

IPC: C07C51/42 ,  C11C1/00

CPC classification number: C11C1/007 ,  C07C51/42

Abstract: Substantially pure stearidonic acid is isolated from a mixture of polyunsaturated fatty acids by fractionating at 25% to 35% by weight solution of fatty acids by high-performance reverse-phase liquid chromatography using a mobile phase of 75% to 95% by weight methanol and 25% to 5% by weight water. The isolated stearidonic acid is used to prepare pharmaceutical compositions which are administered to treat cardiovascular and thrombo-embolic diseases associated with platelet aggregation.

Abstract translation: 通过使用75％至95％重量的甲醇的流动相的高性能反相液相色谱法在25％至35％重量的脂肪酸溶液中分馏从多不饱和脂肪酸的混合物中分离出基本上纯的十八碳四烯酸， 25％至5％重量的水。 分离的十八碳四烯酸用于制备药物组合物，其被施用以治疗与血小板聚集相关的心血管和血栓栓塞性疾病。

公开(公告)号：US20070224200A1

公开(公告)日：2007-09-27

申请号：US11579725

申请日：2005-04-07

Applicant: Samer Elbawab ,  Elodie Masson ,  Daniel Ruggiero ,  Nicolas Wiernsperger ,  Michel Lagarde ,  Lysiane Troncy

Inventor： Samer Elbawab ,  Elodie Masson ,  Daniel Ruggiero ,  Nicolas Wiernsperger ,  Michel Lagarde ,  Lysiane Troncy

IPC: A61K39/395 ,  A61K31/00 ,  A61K31/7105 ,  C12Q1/02 ,  A61K38/43

CPC classification number: G01N33/5023 ,  C12Q1/34 ,  G01N33/5008 ,  G01N33/5064 ,  G01N2500/10

Abstract: The present invention relates to the use of an inhibitor of the expression or activity of the GM3 synthase gene for the treatment of microvascular complications of diabetes, and to a method of screening compounds useful in the treatment and/or prevention of these complications.

Abstract translation: 本发明涉及GM3合酶基因表达或活性抑制剂用于治疗糖尿病微血管并发症的用途，以及筛选用于治疗和/或预防这些并发症的化合物的方法。

公开(公告)号：US08119609B2

公开(公告)日：2012-02-21

申请号：US10421389

申请日：2003-04-23

Applicant: Marc Lecomte ,  Ulriche Denis ,  Clarisse Paget ,  Nicolas Wiernsperger ,  Michel Lagarde

Inventor： Marc Lecomte ,  Ulriche Denis ,  Clarisse Paget ,  Nicolas Wiernsperger ,  Michel Lagarde

IPC: A61K31/33 ,  A61K31/445

CPC classification number: A61K38/07 ,  A61K31/00 ,  A61K31/13 ,  A61K31/198 ,  A61K31/7088 ,  A61K38/06 ,  A61K38/08 ,  A61K38/55 ,  A61K45/06

Abstract: A method of preventing or treating diabetic retinopathy is disclosed including administering to a mammal a therapeutically effective amount of an inhibitor of retinal pericyte apoptosis. Also disclosed is a pharmaceutical composition which treats and/or prevents diabetic retinopathy comprising as an active agent a therapeutically effective amount of at least one inhibitor of retinal pericyte apoptosis and a pharmaceutically acceptable carrier.

Abstract translation: 公开了预防或治疗糖尿病性视网膜病变的方法，其包括向哺乳动物施用治疗有效量的视网膜周细胞凋亡抑制剂。 还公开了治疗和/或预防糖尿病性视网膜病变的药物组合物，其包含治疗有效量的至少一种视网膜周细胞凋亡抑制剂和药学上可接受的载体作为活性剂。

公开(公告)号：US5654290A

公开(公告)日：1997-08-05

申请号：US256825

申请日：1994-09-21

Applicant: Yves Bayon ,  Martine Croset ,  Michel Lagarde ,  Jean Lecerf ,  Frank Thies ,  Jean-Louis Tayot ,  Veronique Chirouze

Inventor： Yves Bayon ,  Martine Croset ,  Michel Lagarde ,  Jean Lecerf ,  Frank Thies ,  Jean-Louis Tayot ,  Veronique Chirouze

IPC: A61K38/00 ,  A61K31/195 ,  A61K31/23 ,  A61K31/685 ,  A61P9/08 ,  A61P9/10 ,  A61P13/02 ,  A61P15/00 ,  C07F9/10 ,  C11B11/00 ,  C11C3/00

CPC classification number: A61K31/23

Abstract: Drug compositions comprised of therapeutically effective amounts of at least one compound selected from the group consisting of:DHA esterified in the form of lysophosphatidyl-choline (lyso-PCDHA) in position sn-2;DHA-phosphatidylcholines (PCDHAs) in which DHA is esterified in position sn-2 and which have an acyl group of [very short length] 2 to 6 carbon atoms in position sn-1;and triglycerides in which DHA is esterified in position sn-2 and which have acyl groups of [very short length] 2 to 6 carbon atoms in positions sn-1 and sn-3.

Abstract translation: PCT No.PCT / FR93 / 01158 Sec。 371日期1994年9月21日 102（e）1994年9月21日PCT 1993年11月24日PCT公布。 公开号WO94 / 12170 日期1994年6月9日由治疗有效量的至少一种选自以下的化合物组成的药物组合物：在位置sn-2中以溶血磷脂酰胆碱（溶血磷脂酰胆碱）的形式酯化的DHA; DHA在位置sn-2中被酯化并且具有位置sn-1具有2至6个[非常短的长度] 2至6个碳原子的酰基的DHA-磷脂酰胆碱（PCDHA） 和其中DHA在位置sn-2被酯化并且在sn-1和sn-3位具有[具有短长度] 2至6个碳原子的酰基的甘油三酯。